Antibodies News and Research

RSS

NeutrobodyPlex nanobodies help monitor SARS-CoV-2 immune responses

Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.

23 Sep 2020

Fourth Phase 3 clinical trial evaluating COVID-19 vaccine begins in the U.S.

A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.

23 Sep 2020

Dextran sulphate-induced tau assemblies cause tau propagation in non-transgenic mice

Accumulation of assembled tau protein in the central nervous system is characteristic of Alzheimer's disease and several other neurodegenerative diseases, called tauopathies.

23 Sep 2020

Study on domestic cats and dogs in COVID-19+ households

A recent survey conducted by a team of scientists from France reveals that pets living with confirmed coronavirus disease 2019 (COVID-19) patients have a high prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. The study is currently available on the bioRxiv* preprint server.

23 Sep 2020

New T-cell-based vaccine strategy provides broader protection against seasonal influenza

As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.

23 Sep 2020

A subunit SARS-CoV-2 vaccine may offer broader protection against virus

A new study published in the preprint server bioRxiv in September 2020 reports on the structure of this protein, as revealed by cryo-electron microscopy (cryoEM).

23 Sep 2020

Molecular dynamic simulations reveal detailed spike-ACE2 interactions

The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.

23 Sep 2020

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020

Confirmed early re-infection with SARS-CoV-2

As scientists strive to develop commercially viable and effective antivirals and vaccines to counter the growing COVID-19 pandemic, there is considerable uncertainty about how long and how durable the immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is. A new paper recently published in the journal Clinical Infectious Disease in September 2020 reports a confirmed case of re-infection with this virus following recovery.

22 Sep 2020

Targeted treatment for systemic lupus erythematosus

A team of researchers from Charité - Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus.

22 Sep 2020

Parkinson's disease diagnosed after SARS-CoV-2

As the COVID-19 pandemic continues to spread, new and unusual chronic sequelae of the disease are cropping up in many medical practices. Now, a new case paper published in The Lancet in September 2020 describes a case of new-onset Parkinson's disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2020

NIH expands clinical trials to evaluate convalescent plasma as a treatment for COVID-19

Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.

22 Sep 2020

Cats’ immune system can deal with SARS-CoV-2, shows study

On 8 May 2020, the Institute of Agrifood Research and Technology (IRTA) reported the case of the first cat infected with SARS-CoV-2 in Spain. It was a 4-year-old cat called Negrito, who lived with a family affected by COVID-19, with one case of death.

22 Sep 2020

Nanoparticle SARS-CoV-2 model could potentially speed the search for drugs

A team of scientists from the National Center for Advancing Translational Sciences and Naval Research Laboratory in Washington, D.C., has developed a new tool that mimics how SARS-CoV-2 -- the virus that causes COVID-19 -- infects a cell, information that could potentially speed the search for treatments against the disease.

22 Sep 2020

Study detects key differences in immune responses of adults and children with COVID-19

The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults.

22 Sep 2020

A cost-effective scalable production of SARS-CoV-2 RBD in yeast

A new study by the Argentinian AntiCovid Consortium and published in the preprint server bioRxiv* in September 2020 reports on the successful characterization of the conformation and stability of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in two different cell systems. This may help to accelerate the development of vaccines and neutralizing antibodies.

21 Sep 2020

Consumption of cooked carrots can also trigger allergic reactions, finds study

The consumption of raw carrots triggers allergic reactions in many people. Contrary to popular belief, cooked carrots can also have this effect.

21 Sep 2020

Oncology nurses should be routinely tested for SARS-CoV-2, warn researchers

Researchers from the NHS Foundation Trust, University of Cambridge and Cambridge Clinical Laboratories have warned that until a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes available, antigen and antibody testing should be carried out among oncology nurses as part of routine patient care.

21 Sep 2020